Source:http://linkedlifedata.com/resource/pubmed/id/12441996
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2002-11-20
|
| pubmed:abstractText |
Metastatic or recurrent cancer continues to be the bane of the urological oncologist. Despite recent improvements in therapeutic strategies and outcomes for clinically localized disease overall survival in patients with the majority of metastatic and recurrent genitourinary malignancies remains relatively unchanged. Modern advances in the field of immunotherapy hold the promise of providing the clinical urologist/oncologist with new tools to fight urological cancer. In this review we discuss the various mAb based strategies currently under investigation for urological oncology as well as the lessons learned from similar approaches in other fields.
|
| pubmed:language |
eng
|
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:author | |
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2615-23
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:articleTitle |
Monoclonal antibody therapy for genitourinary oncology: promise for the future.
|
| pubmed:affiliation |
Department of Urology, University of California at Los Angeles, USA.
|